key: cord-0793992-3m98pj0z
authors: Woehl, Bastien; Lawson, Bree; Jambert, Lucas; Tousch, Jonathan; Ghassani, Afif; Hamade, Amer
title: Four cases of aortic thrombosis in patients with COVID-19
date: 2020-06-08
journal: JACC Case Rep
DOI: 10.1016/j.jaccas.2020.06.003
sha: e1341a3aafe52166425d3398e6750954e7094b6a
doc_id: 793992
cord_uid: 3m98pj0z

Abstract Since the outbreak of the COVID-19 pandemic, increasing evidence suggests that infected patients present a high incidence of thrombotic complications. We describe four cases of aortic thrombosis in patients admitted for COVID-19, between the 26th of March and the 12th of April 2020, in Mulhouse (France).

Since the outbreak of the COVID-19 pandemic, increasing evidence suggests that infected patients present a high incidence of thrombotic complications, such as deep vein thrombosis (1), pulmonary embolism (2) or microvascular thrombosis (3) . All these data suggest the existence of a hypercoagulable state in patients with . This hypercoagulability induced by COVID-19 seems to be responsible for venous thromboembolic events but can also cause arterial complications.

We hereafter describe four cases of aortic thrombosis in patients admitted for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, in our hospital in Mulhouse (France), between the 26th of March and the 12 th of April 2020. Clinical characteristics and biological details are summarized in Table 1 .

First patient was a 64-year-old male with a history of Down syndrome (without congenital heart disease) admitted for hypoxemic pneumonia. COVID-19 was confirmed by reverse-transcriptase-polymerase-chain-reaction (RT-PCR) test. Computed tomography (CT) showed bilateral ground glass opacities (20% lung injury) and a non-obstructive descending aortic thrombus formation ( Figure 1 ). This patient was treated by therapeutic anticoagulation and presented no further complications. He was discharged home at day 6.

Second patient was a 68-year-old male with history of smoking, hypertension, coronary artery disease and deep vein thrombosis ( Table 1 ) admitted for acute bilateral lower limb ischemia. COVID-19 was confirmed by RT-PCR test. CT showed bilateral ground glass opacities (25-50% lung injury) as well as an obstructive thrombosis of the abdominal aorta and a bilateral common iliac arteries thrombosis ( Figure 2 ). An axillo-bifemoral bypass was performed, followed by therapeutic anticoagulation with a good initial result. Patient died 7 days after surgery from a major haemorrhage.

Third patient was a 72-year-old male with history of hypertension, diabetes and coronary artery disease ( Table 1 ) admitted for hypoxic pneumonia. COVID-19 was confirmed by RT-PCR test and CT showed bilateral ground glass opacities (25-50% lung injury). 14 days after admission, the patient suffered from acute ischemia of the right lower limb and CT showed a non-obstructive abdominal aortic thrombosis as well as an obstructive right common iliac artery thrombosis ( Figure 3 ). Patient was treated with therapeutic anticoagulation and surgical thrombectomy was performed 7 days later with a good result.

Fourth patient was a 78-year-old male with history of smoking, hypertension, cardiac hypertrophy and pulmonary embolism ( Table 1 ) admitted for hypoxic pneumonia. COVID-19 was confirmed by RT-PCR test and CT showed bilateral ground glass opacities (25-50% lung injury). 7 days after admission, the patient presented with abdominal pain: abdominal CT showed a non-obstructive abdominal aortic thrombus formation and a right renal infarction consecutive to a thrombosis of the right renal artery (Figure 4 ). Therapeutic anticoagulation was started. Patient presented a cerebral infarction two days later and died.

To our knowledge, this is the first series of aortic thrombosis in COVID-19 patients to be published. Prognosis of patients hospitalized with COVID-19 is often determined by the extent of pulmonary lesions. However vascular complications can also greatly affect outcome as illustrated here. Many authors have recently demonstrated a strong link between COVID-19 and thromboembolism. The physiopathology is not yet fully elucidated, but current data suggest the existence of a hypercoagulability state of patients with COVID-19. A recent paper attributes this state "to excessive inflammation, platelet activation, endothelial dysfunction, and stasis" (5) .

Others have suggested that fibrin formation and polymerization are responsible for this hypercoagulabulity (6) . Therefore recent recommendations insist on thromboprophylactic measures to prevent thromboembolism (4, 7, 8) .

A recent publication found evidence of the presence of virus in endothelial cells (9). One explanation is that the angiotensin converting enzyme 2 (ACE2) receptor that the virus uses to infect cells is widely expressed in endothelial cells. This causes endotheliitis that could explain why Covid-19 patients seem prone to venous and arterial thrombosis. This paper also underlines that patients that are predisposed for endothelial lesions (hypertension, male sex, smoking, diabetes) could be more prone to affection of the endothelium induced by the virus. This was the case with our series of patients who were all male, 75% had hypertension, 50% a history of smoking and 50% had history of coronary artery disease. On the other hand, 2 out of 4 patients also had a history of pulmonary embolism or deep vein thrombosis suggesting an individual predisposition. Finally, outcome of Covid-19 patients affected by arterial thrombosis seems to be severe, as 50% of our patients died. 

High incidence of venous thromboembolic events in anticoagulated severe covid-19 patients

Severe acute proximal pulmonary embolism and covid-19: a word of caution

Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019. Zhonghua jie he he hu xi za zhi zhonghua jiehe he huxi zazhi chin j tuberc respir dis

Isth interim guidance on recognition and management of coagulopathy in covid-19: a comment

Covid-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up

Covid-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure